Aprea Therapeutics (NASDAQ:APRE) Given New $6.00 Price Target at Wedbush

Aprea Therapeutics (NASDAQ:APRE) had its price objective decreased by equities researchers at Wedbush from $7.00 to $6.00 in a research note issued on Thursday,Benzinga reports. The firm currently has an “outperform” rating on the stock.

A number of other research analysts also recently issued reports on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Aprea Therapeutics in a report on Monday, April 20th. HC Wainwright lowered their price target on Aprea Therapeutics from $4.00 to $1.20 and set a “buy” rating for the company in a research report on Tuesday, March 31st. Zacks Research raised shares of Aprea Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, February 16th. Finally, Oppenheimer assumed coverage on Aprea Therapeutics in a research report on Thursday, May 7th. They set an “outperform” rating and a $5.00 target price on the stock. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $4.07.

Aprea Therapeutics Stock Performance

Shares of NASDAQ APRE opened at $0.90 on Thursday. Aprea Therapeutics has a fifty-two week low of $0.55 and a fifty-two week high of $2.22. The company has a market cap of $11.18 million, a price-to-earnings ratio of -0.46 and a beta of 1.48. The business’s 50 day moving average price is $0.82 and its 200-day moving average price is $0.92.

Aprea Therapeutics (NASDAQ:APRE) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.01. Aprea Therapeutics had a negative return on equity of 96.33% and a negative net margin of 4,405.59%. Sell-side analysts predict that Aprea Therapeutics will post -0.87 earnings per share for the current year.

Hedge Funds Weigh In On Aprea Therapeutics

Institutional investors have recently bought and sold shares of the company. AIGH Capital Management LLC boosted its position in shares of Aprea Therapeutics by 174.1% during the 1st quarter. AIGH Capital Management LLC now owns 1,015,541 shares of the company’s stock worth $775,000 after purchasing an additional 645,000 shares during the period. Jane Street Group LLC acquired a new stake in shares of Aprea Therapeutics in the fourth quarter valued at $40,000. Finally, DRW Securities LLC purchased a new stake in shares of Aprea Therapeutics in the 4th quarter valued at $103,000. 34.19% of the stock is owned by hedge funds and other institutional investors.

Aprea Therapeutics Company Profile

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.